Peijia Medical, a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, has announced that its wholly-owned subsidiary, Achieva Medical has entered into an exclusive distribution agreement with Jiangsu NowYon Medical. The agreement marks a significant milestone in the expansion of Peijia Medical's Neurointerventional Business in the Greater China region.

Under the terms of the agreement, Achieva Medical has been appointed as the exclusive distributor for NowYon Medical's innovative YonFlow flow diverter, the first retrievable stent system after complete release globally.

In January 2023, the product passed the innovative medical device review and was accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the National Medical Products Administration (NMPA).

In addition, the application for the registration approval of YonFlow has been submitted to the NMPA, which is expected to be approved soon.

Peijia Medical now has three transcatheter aortic valve replacement (TAVR) systems and sixteen neurointerventional devices commercialised in China and various innovative product candidates at different stages of development.

On the other hand, Jiangsu NowYon Medical's product pipeline encompasses a range of solutions for hemorrhagic stroke, ischemic stroke and vascular access, including flow diverters, stent retrievers, aspiration catheters, balloon microcatheter, microcatheter, etc.